Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB

Table 2

Association of ORR/DCR and clinical characteristics.

Characteristics ()		(%)	Overall response rate (ORR)		Disease control rate (DCR)
			% ()	value	% ()	value
Overall			42.4% (36/85)		68.2% (58/85)
Gender	Male	62 (72.9)	40.3% (25/62)	0.534	66.1% (41/62)	0.493
	Female	23 (27.1)	47.8% (11/23)		73.9% (17/23)
Age	<70 y	57 (67.1)	42.1% (24/57)	0.947	70.2% (40/57)	0.584
	≥70 y	28 (32.9)	42.9% (12/28)		64.3% (18/28)
Smoking	No	46 (54.1)	47.8% (22/46)	0.267	69.6% (32/46)	0.775
	Yes	39 (45.9)	35.9% (14/39)		66.7% (26/39)
Histology	LUSC	37 (43.5)	40.5% (15/37)	0.767	62.2% (23/37)	0.291
	LUAD	48 (56.5)	43.8% (21/48)		72.9% (35/48)
Stage	IVA	38 (44.7)	42.1% (16/38)	0.967	65.8% (25/38)	0.663
	IVB	47 (55.3)	42.6% (20/47)		70.2% (33/47)
Line of treatment	<3	71 (83.5)	46.5% (33/71)	0.083	71.8% (51/71)	0.109
	≥3	14 (16.5)	21.4% (3/14)		50.0% (7/14)
NLR	<5	49 (57.6)	53.1% (26/49)	0.02	85.7% (42/49)	<0.001
	≥5	36 (42.4)	27.8% (10/36)		44.4% (16/36)
dNLR	<3	45 (52.9)	57.8% (26/45)	0.002	88.9% (40/45)	<0.001
	≥3	40 (47.1)	25.0% (10/40)		45.0% (18/40)
LDH	<210	39 (45.9)	41.0% (16/39)	0.82	74.4% (29/39)	0.264
	≥210	46 (54.1)	43.5% (20/46)		63.0% (29/36)
LMR	<1.8	22 (25.9)	22.7% (5/22)	0.03	45.5% (10/22)	0.008
	≥1.8	63 (74.1)	49.2% (31/63)		76.2% (48/63)
ALB	<35	20 (23.6)	15.0% (3/20)	0.005	50.0% (10/20)	0.045
	≥35	65 (76.5)	50.8% (33/65)		73.8% (48/65)
PAB	<17	35 (41.1)	34.3% (12/35)	0.208	62.9% (22/35)	0.373
	≥17	50 (58.8)	48.0% (24/50)		72.0% (36/50)
LIPI	Intermediate/poor	21 (24.7)	52.4% (11/21)	0.284	90.5% (19/21)	0.012
	Good	64 (75.3)	39.1% (25/64)		60.9% (39/64)